|
1
|
Garcia I, Vizoso F, Martin A, et al:
Clinical significance of the epidermal growth factor receptor and
HER2 receptor in resectable gastric cancer. Ann Surg Oncol.
10:234–241. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yonemura Y, Ninomiya I, Yamaguchi A, et
al: Evaluation of immunoreactivity for erbB-2 protein as a marker
of poor short term prognosis in gastric cancer. Cancer Res.
51:1034–1038. 1991.PubMed/NCBI
|
|
3
|
Tanner M, Hollmen M, Junttila TT, et al:
Amplification of HER-2 in gastric carcinoma: association with
Topoisomerase IIalpha gene amplification, intestinal type, poor
prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar
|
|
5
|
Hayashi M, Inokuchi M, Takagi Y, et al:
High expression of HER3 is associated with a decreased survival in
gastric cancer. Clin Cancer Res. 14:7843–7849. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
7
|
Kovtun YV and Goldmacher VS: Cell killing
by antibody-drug conjugates. Cancer Lett. 255:232–240. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lewis Phillips GD, Li G, Dugger DL, et al:
Targeting HER2-positive breast cancer with trastuzumab-DM1, an
antibody-cytotoxic drug conjugate. Cancer Res. 68:9280–9290.
2008.PubMed/NCBI
|
|
9
|
Erickson HK, Lewis Phillips GD, Leipold
DD, et al: The effect of different linkers on target cell
catabolism and pharmacokinetics/pharmacodynamics of trastuzumab
maytansinoid conjugates. Mol Cancer Ther. 11:1133–1142. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oroudjev E, Lopus M, Wilson L, et al:
Maytansinoid-antibody conjugates induce mitotic arrest by
suppressing microtubule dynamic instability. Mol Cancer Ther.
9:2700–2713. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lopus M, Oroudjev E, Wilson L, et al:
Maytansine and cellular metabolites of antibody-maytansinoid
conjugates strongly suppress microtubule dynamics by binding to
microtubules. Mol Cancer Ther. 9:2689–2699. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Junttila TT, Li G, Parsons K, Phillips GL
and Sliwkowski MX: Trastuzumab-DM1 (T-DM1) retains all the
mechanisms of action of trastuzumab and efficiently inhibits growth
of lapatinib insensitive breast cancer. Breast Cancer Res Treat.
128:347–356. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barok M, Tanner M, Koninki K and Isola J:
Trastuzumab-DM1 is highly effective in preclinical models of
HER2-positive gastric cancer. Cancer Lett. 306:171–179. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
LoRusso PM, Weiss D, Guardino E, Girish S
and Sliwkowski MX: Trastuzumab emtansine: a unique antibody-drug
conjugate in development for human epidermal growth factor receptor
2-positive cancer. Clin Cancer Res. 17:6437–6447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Franklin MC, Carey KD, Vajdos FF, Leahy
DJ, de Vos AM and Sliwkowski MX: Insights into ErbB signaling from
the structure of the ErbB2-pertuzumab complex. Cancer Cell.
5:317–328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baselga J, Cortes J, Kim SB, et al:
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamashita-Kashima Y, Iijima S, Yorozu K,
et al: Pertuzumab in combination with trastuzumab shows
significantly enhanced antitumor activity in HER2-positive human
gastric cancer xenograft models. Clin Cancer Res. 17:5060–5070.
2011. View Article : Google Scholar
|
|
18
|
Fujimoto-Ouchi K, Sekiguchi F, Yasuno H,
Moriya Y, Mori K and Tanaka Y: Antitumor activity of trastuzumab in
combination with chemotherapy in human gastric cancer xenograft
models. Cancer Chemother Pharmacol. 59:795–805. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujimoto-Ouchi K, Sekiguchi F and Tanaka
Y: Antitumor activity of combinations of anti-HER-2 antibody
trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in
human breast cancer models. Cancer Chemother Pharmacol. 49:211–216.
2002.PubMed/NCBI
|
|
20
|
Baselga J, Gelmon KA, Verma S, et al:
Phase II trial of pertuzumab and trastuzumab in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer that progressed during prior trastuzumab therapy. J Clin
Oncol. 28:1138–1144. 2010. View Article : Google Scholar
|
|
21
|
Hurvitz SA, Dirix L, Kocsis J, Gianni L,
Lu MJ, Vinholes J, Song C, Tong B, Chu Y-W and Perez EA:
Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T)
in previously untreated HER2-positive metastatic breast cancer
(MBC): primary results of a randomized, multicenter, open-label
phase II study (TDM4450g/BO21976). Eur J Cancer. 47:S3302011.
View Article : Google Scholar
|
|
22
|
Baselga J and Swain SM: Novel anticancer
targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Spector NL and Blackwell KL: Understanding
the mechanisms behind trastuzumab therapy for human epidermal
growth factor receptor 2-positive breast cancer. J Clin Oncol.
27:5838–5847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scheuer W, Friess T, Burtscher H,
Bossenmaier B, Endl J and Hasmann M: Strongly enhanced antitumor
activity of trastuzumab and pertuzumab combination treatment on
HER2-positive human xenograft tumor models. Cancer Res.
69:9330–9336. 2009. View Article : Google Scholar
|
|
26
|
El-Sahwi K, Bellone S, Cocco E, et al: In
vitro activity of pertuzumab in combination with trastuzumab in
uterine serous papillary adenocarcinoma. Br J Cancer. 102:134–143.
2010. View Article : Google Scholar : PubMed/NCBI
|
